$10.17
+0.78 (+8.31%)
Open$9.83
Previous Close$9.39
Day High$10.26
Day Low$9.51
52W High$12.54
52W Low$2.24
Volume—
Avg Volume4.02M
Market Cap1.75B
P/E Ratio—
EPS$-0.80
SectorBiotechnology
Analyst Ratings
Strong Buy
16 analysts
Price Target
+131.6% upside
Current
$10.17
$10.17
Target
$23.55
$23.55
$16.79
$23.55 avg
$35.63
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 3.52M | 4.47M | 58.57M |
| Net Income | -144,516,159 | -165,329,278 | -8,944,093 |
| Profit Margin | -4,113.7% | -3,908.0% | -15.3% |
| EBITDA | -136,227,202 | -164,504,692 | -15,160,350 |
| Free Cash Flow | — | — | -10,726,027 |
| Rev Growth | -21.3% | -21.3% | +10.3% |
| Debt/Equity | 0.00 | 0.00 | 0.34 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |